Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer

 
• By John Davis
Stop
Competitive Pressures Can Lead To A Rethink of Development Strategies • Source: Shutterstock

More from Immuno-oncology

More from Anticancer